Sara Strandberg

Cross Modality Image Translation In Medical Imaging Using Generative Frameworks

Giulia Romoli, Alessia Capoccia, Filippo Ruffini, Francesco Di Feola et autres

Medical image-to-image (I2I) translation enables virtual scanning, i.e. the synthesis of a target imaging modality from a source one without additional acquisitions. Despite growing interest, most proposed methods operate on 2D slices, are evaluated on isolated tasks with different experimental set-ups and …

Cross Modality Image Translation In Medical Imaging Using Generative Frameworks

Giulia Romoli, Alessia Capoccia, Filippo Ruffini, Francesco Di Feola et autres

Medical image-to-image (I2I) translation enables virtual scanning, i.e. the synthesis of a target imaging modality from a source one without additional acquisitions. Despite growing interest, most proposed methods operate on 2D slices, are evaluated on isolated tasks with different experimental set-ups and …

Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095

Karin Söderkvist, Maira Zia, Adalsteinn Gunnlaugsson, Andreas Josefsson et autres

BACKGROUND: Metastasis-directed stereotactic body radiotherapy (MD-SBRT) has shown promise in retrospective and phase II studies for oligometastatic hormone-sensitive prostate cancer. However, prospective randomized phase III data-particularly in newly diagnosed cases and in combination with androgen deprivation therapy and next-generation androgen receptor pathway …

se, no (code pays fourni par la source)

Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095

Karin Söderkvist, Maira Zia, Adalsteinn Gunnlaugsson, Andreas Josefsson et autres

Abstract Background Metastasis-directed stereotactic body radiotherapy (MD-SBRT) has shown promise in retrospective and phase II studies for oligometastatic hormone-sensitive prostate cancer. However, prospective randomized phase III data—particularly in newly diagnosed cases and in combination with androgen deprivation therapy and next-generation androgen receptor …

se, no (code pays fourni par la source)

Additional file 1 of Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095

Karin Söderkvist, Maira Zia, Adalsteinn Gunnlaugsson, Andreas Josefsson et autres

Supplementary Material 1.

se, no (code pays fourni par la source)

Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095

Karin Söderkvist, Maira Zia, Adalsteinn Gunnlaugsson, Andreas Josefsson et autres

Abstract Background Metastasis-directed stereotactic body radiotherapy (MD-SBRT) has shown promise in retrospective and phase II studies for oligometastatic hormone-sensitive prostate cancer. However, prospective randomized phase III data—particularly in newly diagnosed cases and in combination with androgen deprivation therapy and next-generation androgen receptor …

se, no (code pays fourni par la source)

Additional file 2 of Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095

Karin Söderkvist, Maira Zia, Adalsteinn Gunnlaugsson, Andreas Josefsson et autres

Supplementary Material 2.

se, no (code pays fourni par la source)

Additional file 2 of Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095

Karin Söderkvist, Maira Zia, Adalsteinn Gunnlaugsson, Andreas Josefsson et autres

Supplementary Material 2.

se, no (code pays fourni par la source)

Additional file 1 of Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095

Karin Söderkvist, Maira Zia, Adalsteinn Gunnlaugsson, Andreas Josefsson et autres

Supplementary Material 1.

se, no (code pays fourni par la source)

2[18F]-FDG-PET/CT and 2[18F]-FDG-PET/MRI in primary staging of epithelial ovarian cancer – an early interim analysis of a prospective clinical trial

Karolina Rosendahl, Malin Båtsman, Ulrika Ottander, Sara Strandberg

Objective: In epithelial ovarian cancer (EOC), 2-fluorine-18-fluoro-deoxy-glucose (2-[18F]-FDG)-positron emission tomography (PET) with computed tomography (CT) outperforms CT and magnetic resonance imaging (MRI) in metastasis detection. The aim of this early interim study was to assess feasibility of the study workflow to evaluate …

se (code pays fourni par la source)

Local staging of de novo prostate cancer using mpMRI, PSMA-PET and PSMA-PET/mpMRI – a comparative study

Josefine Grefve, Sara Strandberg, Joakim Jonsson, Angsana Keeratijarut Lindberg et autres

BACKGROUND: Accurate diagnosis and staging are essential for optimal treatment planning of prostate cancer. By combining functional and anatomical imaging, PSMA-PET/mpMRI offers a potential to improve lesion detection and enhance staging accuracy. This study aimed to evaluate the diagnostic performance of lesion …

se, dk (code pays fourni par la source)

Ultra-hypofractionated radiotherapy with focal boost for high-risk localized prostate cancer (HYPO-RT-PC-boost): in silico evaluation with histological reference

Erik Nilsson, A. Nilsson, Joakim Jonsson, Kristina Sandgren et autres

BACKGROUND AND PURPOSE: The study aims to evaluate dosimetric properties of hypofractionated treatment plans integrating focal boost, using registered whole-mount histopathology (WMHP) as reference standard. METHODS: Fifteen men from the PAMP trial (EudraCT: 2015-005046-55) were included. Participants had ≥ 1 ISUP Grade …

se (code pays fourni par la source)